BCL2 and acute myeloid leukemia: However, further research has shown that only co-targeting of BCL2 and MCL1 is effective in AML cell lines with intrinsic or acquired resistance to BH3 mimetics or engineered to genetically overexpress BCL2 or BCL2A1 or downregulate BAX.